Key result
Clinical surveillance of the Novacor LVAS demonstrated 91.5% freedom from wear at 3 years, which broadly paralleled the 87.4% freedom from wear observed in earlier in vitro testing.
Why the study?
Does the clinical long-term performance and wear of the Novacor LVAS parallel demonstrated in vitro reliability in patients implanted for more than 1 year?
Observational (n=37)
Does the clinical long-term performance and wear of the Novacor LVAS parallel demonstrated in vitro reliability in patients implanted for more than 1 year?
Clinical surveillance of the Novacor LVAS demonstrates long-term durability and wear patterns that closely parallel in vitro reliability testing, enabling elective replacement.
Answers are grounded in this paper and cite their sources.
Supports Novacor LVAS durability in extended use; hypothesis-generating and should not yet alter surveillance.
Since the first implant of the Novacor wearable left ventricular assist system (LVAS) in 1993, median implant duration worldwide has increased from 93 days (max 2.2 years) to 202 days (max 4.1 years) in May 2001. In vitro reliability/durability testing of the Novacor LVAS has previously demonstrated a mean time to failure of 4.2 (3.04-5.59) years. These tests revealed a single failure mode--main bearing wear--with measurable symptoms gradually appearing before degradation of pump function. An ongoing clinical study of 37 recipients implanted for more than 1 year has shown that a simple noninvasive method of pump surveillance, derived from the in vitro experience, is well tolerated in the clinical setting. The overall clinical experience is consistent with in vitro reliability/durability tests that demonstrated 99.9%, 98.5%, and 87.4% freedom from wear at 1, 2, and 3 years (80% confidence). So far, the clinical study has shown 99.4%, 91.5%, and 91.5% freedom from wear at the same 1, 2, and 3 year intervals (95% confidence). Furthermore, the clinical findings have corroborated the in vitro experience that the wear mechanism is generally measurable and gradual, enabling elective clinical LVAS replacement or transplantation. Clinical valve performance was also monitored, using an exercise protocol and collecting comparative data on peak flows across the valves. It was determined that developing valve dysfunction could be diagnosed early and, in the failures that did occur (n = 2), these were related to the patient's disease state. In conclusion, although clinical conditions exposed the LVAS to a wide range of different environmental and hydraulic stresses, the surveillance program described appears practical and reliable, and its findings broadly parallel those of the earlier in vitro study. Additional data needed to complete formal validation continue to be collected.
No takes yet. Share an insight, caveat, or question.
Wheeldon et al. (2002) conducted an observational in Heart failure requiring left ventricular assist system (n=37). Novacor LVAS vs. In vitro testing was evaluated on Freedom from wear at 3 years. Clinical surveillance of the Novacor LVAS demonstrated 91.5% freedom from wear at 3 years, which broadly paralleled the 87.4% freedom from wear observed in earlier in vitro testing.
Synapse has enriched 10 related papers. Consider them for comparative context: